Search Results
Your search for s matches 7010 pages
Showing 4601 - 4650Carboplatin/Paclitaxel Tops Oxaliplatin/Capecitabine as Neoadjuvant Regimen for Esophageal Cancer
The United Kingdom’s phase II NEOSCOPE trial compared the toxicity and efficacy of two preoperative chemoradiation regimens—carboplatin/paclitaxel and oxaliplatin/capecitabine—and judged one to be the winner. “CarPacRT passed the prespecified efficacy criteria for taking forward to phase III, but...
Cost in the Context of Value for Cancer Medicines
Bringing new cancer therapies through the discovery and development process entails considerable risk and many years of study. It also requires substantial investment and incentives from the public and private sectors to fuel future investment and discovery. A system that rewards advances in cancer ...
Inherited Genetic Variations That Lead to Severe Drug Toxicity in Pediatric Leukemia Discovered
An international research team has determined how inherited gene variations lead to severe drug toxicity that may threaten chances for a cure in children with leukemia. St. Jude Children’s Research Hospital scientists led the study, results of which set the stage to expand the use of a...
Fecal Immunochemical Test Sensitive and Effective for Annual Colorectal Cancer Screening
Annual screening with the fecal immunochemical test is highly sensitive for detecting colorectal cancer and “is feasible and effective for population-level colorectal cancer screening,” according to a large-scale retrospective cohort study assessing the fecal immunochemical...
Increased Risk of Severe Neurocognitive Impairment in Adult Survivors of Pediatric CNS Tumors
As reported in the Journal of Clinical Oncology by Brinkman et al, a study in the St. Jude Lifetime Cohort showed that adult survivors of pediatric central nervous system (CNS) tumors are at increased risk of severe neurocognitive impairment. Study Details The study involved 224 survivors of CNS...
Dutch Study Shows Increased Risk of Second Cancer for Survivors of Hodgkin Lymphoma During Long-Term Follow-up
In a Dutch study reported in The New England Journal of Medicine, Schaapveld et al found that survivors of Hodgkin lymphoma treated between 1965 and 2000 were at a 4.6-fold greater risk of second cancer vs the general population during long-term follow-up. There was no significant difference in the ...
Younger T Cells May Improve Immunotherapy for Pediatric Cancer
Pediatric oncologists from The Children’s Hospital of Philadelphia (CHOP) have investigated techniques to improve and broaden a novel personalized cell therapy to treat children with cancer. The researchers say that a patient’s outcome may be improved if clinicians select specific...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians. The guideline recommendations were formulated by a multidisciplinary expert work group and are based on...
Possible Marker for Recurring HPV-Linked Oropharyngeal Cancers
A retrospective analysis of human papillomavirus (HPV) antibodies in patients treated for oropharyngeal cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, said scientists at The Johns Hopkins...
Alectinib in ALK-Positive Metastatic NSCLC After Crizotinib
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 11, 2015, alectinib (Alecensa) was granted...
Richard ‘Buz’ Cooper, MD, Noted Health Policy Expert, Dies at 79
Addressing disparities of cancer care that result in poorer outcomes among certain populations remains a persistent challenge in the oncology community and in the health-care system at large. It is, to a large degree, a medical story of haves and have-nots. Richard “Buz” Cooper, MD, a preeminent...
Hospira Foundation Donates $5 Million to the University of Chicago Medicine
The Hospira Foundation has donated $5 million to the University of Chicago Medicine to create the Hospira Foundation Professorship in Oncology. The Hospira Foundation Professor will be a key leader in advancing the University of Chicago Medicine’s cancer research objectives, which include...
Selected Abstracts From 2015 ASH Annual Meeting: Part 2
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting therapeutics in acute leukemias and myelodysplastic syndromes. For five other top abstracts on therapies for acute leukemias and myelodysplastic ...
Increased Incidence of in Situ and Invasive Melanoma in Denmark
In a study reported in JAMA Dermatology,1 Neel Maria Helvind, MD, of the University Hospital Rigshospitalet, Copenhagen, Denmark, and colleagues analyzed the increases in melanoma incidence seen in Denmark between 1985 and 2012. Over that time, the incidence of malignant melanoma doubled to rates...
Bone Loss Associated With Leukemia Therapy Occurs Sooner Than Previously Thought
Investigators at Children’s Hospital Los Angeles (CHLA) have found that significant bone loss occurs during the first month of chemotherapy for acute lymphoblastic leukemia (ALL), which is far earlier than previously assumed. Results of the study were published by Orgel et al in the...
World Cancer Day 2016: We Can. I Can.
Cancer will kill more than 8 million people worldwide this year, which is equivalent to the entire population of New York. Half of these will be people of working age (30–69 years old). It has been estimated that the cost implications on world economies caused by cancer and the other...
ASCO Names Cancer Advance of the Year: Immunotherapy
At a Capitol Hill briefing today, ASCO announced immunotherapy as the top cancer advance of the year. Recent breakthroughs in immunotherapy—along with almost 60 other important cancer research advances—are described in ASCO's just-released report, Clinical Cancer Advances 2016: ASCO's...
American College of Physicians Issues Advice, Raises Questions About Best Practices for Hematuria as a Sign of Cancer
In some patients, blood in the urine, or hematuria, may be the only warning sign of cancer in the urinary tract. A new report from the American College of Physicians’ (ACP) High Value Care Task Force published by Nielsen et al in Annals of Internal Medicine issues advice for physicians on how ...
High Rate of Local Control Reported With High-Dose Hypofractionated Proton Beam Therapy in Liver Cancers
High-dose hypofractionated proton beam therapy produced a high rate of local control in patients with localized unresectable hepatocellular carcinoma or intrahepatic cholangiocarcinoma, according to a phase II study reported in the Journal of Clinical Oncology by Hong et al. Study Details In the...
Dr. Abraham’s Top-10 Picks for the Most Clinically Relevant Breast Cancer Studies of 2015
Sparano JA, Gray RJ, Makower DF, et al: Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373:2005-2014, 2015. Chagpar AB, Killelea BK, Tsangaris TN, et al: A randomized, controlled trial of cavity shave margins in breast cancer. N Engl J Med 373:503-510, 2015....
Selected Abstracts From 2015 San Antonio Breast Cancer Symposium
The 2015 San Antonio Breast Cancer Symposium (SABCS), hosted by the American Association for Cancer Research, the Cancer Therapy & Research Center at The University of Texas Health Sciences Center at San Antonio, and Baylor College of Medicine, was held in December 2015. As has been true for...
Studies Confirm and Extend the Benefits of Ixazomib in Multiple Myeloma
Patients with multiple myeloma now have access to an all-oral regimen, with the recent approval of the oral proteasome inhibitor ixazomib (Ninlaro) in previously treated patients. New pairings for the drug in relapsed/refractory and newly diagnosed patients are being studied, with investigators...
Pembrolizumab Label Updated With New Clinical Trial Information
Late in 2015, the U. S. Food and Drug Administration (FDA) expanded the label for pembrolizumab (Keytruda), a humanized antibody, to include the initial treatment of patients with unresectable or metastatic melanoma. Previously, pembrolizumab had received accelerated approval in patients with...
Two Contenders for Second-Line Treatment of Advanced Renal Cell Carcinoma
Options for second-line therapy of advanced/metastatic renal cell carcinoma are expanding. Updates from the CheckMate 025 and METEOR trials presented at the 2016 Genitourinary Cancers Symposium solidify the value of both nivolumab (Opdivo, an immune checkpoint inhibitor) and cabozantinib...
Study Finds Association Between Androgen-Deprivation Therapy in Prostate Cancer and Risk of Alzheimer’s Disease
In a retrospective analysis reported in the Journal of Clinical Oncology, Nead et al found that use of androgen-deprivation therapy in the treatment of prostate cancer was associated with an increased risk of subsequent Alzheimer’s disease. Study Details In the study, a text-processing...
Material and Psychological Financial Hardship for U.S. Cancer Patients
In a population-based study reported in the Journal of Clinical Oncology, Yabroff et al found that cancer and its treatment were associated with material financial hardship for 29% and psychological financial hardship for 32% of patients aged 18 to 64 years in the United States. Financial hardship...
Study Finds Need for Improved End-of-Life Care for Parents With Terminal Cancer
Care for mothers with terminal cancer could be improved to help resolve their psychological distress and to help surviving family members cope, a study by University of North Carolina at Chapel Hill researchers have found. Based on the study findings published by Park et al in the journal BMJ...
Increased Breast Cancer Risk Reported in Childhood Sarcoma and Leukemia Survivors With No History of Chest Radiotherapy
In an analysis of the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Henderson et al found that childhood survivors of sarcoma and leukemia with no history of chest radiotherapy were at an increased risk of breast cancer. Increased Risk The study included data from...
Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes
Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 3251, “An Open-Label, Phase II, Dose-Finding Study of Sotatercept (ACE-011) in Patients With Low or Intermediate-1–Risk Myelodysplastic Syndromes or Nonproliferative Chronic Myelomonocytic Leukemia and Anemia Requiring...
Hope S. Rugo, MD, on the Phase II FIRST Study
Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S6-04, “Fulvestrant 500 mg vs anastrozole as first-line treatment for advanced breast cancer: Overall survival from the phase II FIRST study,” presented by John F.R. Robertson, MD.
Hope S. Rugo, MD, on Dietary Intervention as Adjuvant Breast Cancer Therapy
Hope S. Rugo, MD, of the University of California, San Francisco, discusses abstract S5-08, “Final survival analysis from the randomized Women's Intervention Nutrition Study (WINS) evaluating dietary intervention as adjuvant breast cancer therapy,” presented by Rowan T. Chlebowski, MD.
Edith A. Perez, MD, on Stromal Tumor-Infiltrating Lymphocytes in Early-Stage HER2-Positive Breast Cancer
Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06, “Stromal tumor-infiltrating lymphocytes: In the Alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit.”
Lee S. Schwartzberg, MD, FACP, and Ian E. Krop, MD, PhD, on PI3K and PD-L1 Inhibition Data
Lee S. Schwartzberg, MD, FACP of The West Clinic and Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute discuss the FERGI trial and data from phase I and phase II studies.
Crystal S. Denlinger, MD, on Management of Anthracycline-Induced Cardiac Toxicity
Crystal S. Denlinger, MD, of Fox Chase Cancer Center, discusses cardiac toxicities in cancer survivors, a new topic for the NCCN Survivorship Guidelines this year, and the need for more research on this important side effect, including prevention and surveillance.
Samuel M. Silver, MD, PhD, and David S. Ettinger, MD, on the Characteristics of an Optimal Clinical Practice Guideline
Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and David S. Ettinger, MD, of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discuss the evolution of the NCCN Guidelines, the importance of including palliative care and survivorship...
Nicholas David James, MD, PhD, and Celestia S. Higano, MD, on Results From the STAMPEDE Trial on Hormone-Naive Prostate Cancer
Celestia S. Higano, MD, of the University of Washington, and Nicholas David James, MD, PhD, of Warwick Medical School, discuss data showing improvements in survival from adding docetaxel in men starting long-term hormone therapy for the first time (Abstract 5001).
Christian Carrie, MD, and Celestia S. Higano, MD, on Results of the GETUG-AFU 16 Trial on Prostate Cancer
Christian Carrie, MD, of Centre Léon Bérard, and Celestia S. Higano, MD, of the University of Washington, discuss short hormonal therapy and radiotherapy as salvage treatment for relapse after radical prostatectomy (Abstract 5006).
Lee S. Schwartzberg, MD, on ICLIO: Adopting Immunotherapy in the Community Setting
Lee S. Schwartzberg, MD, of The West Clinic, describes a new initiative of the Association of Community Cancer Centers, designed to speed the adoption of immunotherapeutics in the community setting, where 60% of cancer patients are treated.
Allison J. Applebaum, PhD, and William S. Breitbart, MD, on Creating Meaning-Centered Psychotherapy for Cancer Patients
Allison J. Applebaum, PhD, and William S. Breitbart, MD, of Memorial Sloan Kettering Cancer Center, discuss the early days of this new treatment for despair and distress in cancer patients.
Allison J. Applebaum, PhD, and William S. Breitbart, MD, on Workshops in Meaning-Centered Psychotherapy
Allison J. Applebaum, PhD, and William S. Breitbart, MD, of Memorial Sloan Kettering Cancer Center, discuss a meaning-centered psychotherapy workshop they conducted for an international group of clinicians.
Allison J. Applebaum, PhD, and William S. Breitbart, MD, on Adapting Meaning-Centered Psychotherapy for Caregivers
Allison J. Applebaum, PhD, and William S. Breitbart, MD, of Memorial Sloan Kettering Cancer Center, explain how they brought this new treatment to help stressed caregivers of loved ones with cancer.
Allison J. Applebaum, PhD, and William S. Breitbart, MD, on Meaning-Centered Psychotherapy for Cancer Patients
Allison J. Applebaum, PhD, and William S. Breitbart, MD, of Memorial Sloan Kettering Cancer Center, discuss a powerful treatment approach that is grounded in a moving personal story.
Roy S. Herbst, MD, PhD, on Results From SWOG S0819
Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).
Matti S. Aapro, MD, on Geriatric Oncology: A Multidisciplinary Approach for Positive Outcomes
Matti S. Aapro, MD, of IMO Clinique de Genolier, offered a case presentation and a cross-disciplinary approach to finding the best way to effect a cure with minimal impact on quality of life.
Jennifer S. Temel, MD's Expert Perspective: Palliative Care in 2015
As Steering Committee Chair of this year’s symposium, Jennifer S. Temel, MD, of Massachusetts General Hospital, discusses the goals and highlights of the meeting.
Srikala S. Sridhar, MD: Bladder Cancer Update
Srikala S. Sridhar, MD, of the Princess Margaret Cancer Centre, summarizes important papers presented on bladder and urothelial cancers, including perspectives on immunotherapies and radiotherapies.
Mary S. McCabe, RN, on Risk-Based Health Care of Cancer Survivors
Mary McCabe, RN, of Memorial Sloan Kettering Cancer Center, discusses various models of delivering survivorship care.
Richard S. Finn, MD, on Advanced Hepatocellular Carcinoma: Expert Perspective
Richard S. Finn, MD, of the University of California Los Angeles Medical Center, summarizes a session on treatments for advanced hepatocellular carcinoma (Abstract 192).
Pilot Study Indicates Little Activity of Vemurafenib in Metastatic BRAF-Mutated Colorectal Cancer
In a phase II pilot study reported in the Journal of Clinical Oncology, Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found little clinical activity of vemurafenib (Zelboraf) in patients with metastatic BRAF-mutated colorectal cancer.1 The BRAF V600E...
Cancer Incidence in Indigenous People in Australia, New Zealand, Canada, and the United States
In a population-based study reported in The Lancet Oncology, Suzanne P. Moore, PhD, of Charles Darwin University, Northern Territory, Australia, and colleagues compared cancer incidence in indigenous people in Australia, New Zealand, Canada, and the United States with the incidence in nonindigenous ...
